RAJAF
Cordyceps Sunshine Biotech Holdings Co., Ltd.Company with tickers: RAJAF
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $1,245,348 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $484,607 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Gross Profit | $760,741 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Operating Expenses | $901,869 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Research & Development | — | ||||
| Operating Income | $-141,128 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Net Income | $-154,822 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| EPS (Basic) | $0.00 | USD/shares | 2025-12-31 | 20-F | 2026-05-15 |
| EPS (Diluted) | $0.00 | USD/shares | 2025-12-31 | 20-F | 2026-05-15 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|
| Product Sales | — | — | $601,570 | $1,200,541 | $1,069,943 |
| Revenue Related Parties | — | $53,304 | $126,856 | $52,943 | $175,405 |
| Sales Of Cordyceps | $879,318 | — | — | — | — |
| Training | — | — | $154,107 | — | — |